<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390701</url>
  </required_header>
  <id_info>
    <org_study_id>HyperTENSion</org_study_id>
    <nct_id>NCT01390701</nct_id>
  </id_info>
  <brief_title>Blood Pressure Lowering Effect of Transcutaneous Electrical Nerve Stimulation</brief_title>
  <acronym>HyperTENSion</acronym>
  <official_title>Blood Pressure Lowering Effect of Low-frequency Transcutaneous Electrical Nerve Stimulation and Felodipin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the blood pressure reducing property of
      transcutaneous electrical nerve stimulation with the blood pressure reducing drug felodipin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is a major risk factor for development of several vascular complications and is
      common world wide. Drug treatment is often necessary to achieve adequate blood pressure
      reduction but blood pressure control in studied countries is unsatisfactory low. Reasons for
      failure in treatment are several. Among others reasons intolerable side-effects may prevent
      successful treatment irrespective of the number of drugs.

      Transcutaneous electrical nerve stimulation (TENS) constitutes no risk of interaction with
      pharmacological agents and previous studies have reported blood pressure reduction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure reduction</measure>
    <time_frame>four weeks</time_frame>
    <description>Office blood pressure measurement and 24-h ambulatory blood pressure monitoring after four week periods of treatment in a cross-over design with intervening four week washout and subsequent four week follow-up</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>transcutaneous electr. nerve stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>felodipin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcutaneous electrical nerve stimulation</intervention_name>
    <description>30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.</description>
    <arm_group_label>transcutaneous electr. nerve stimulation</arm_group_label>
    <other_name>2 Hz Primo Pro stimulators (CefarCompex, Sweden).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>felodipin</intervention_name>
    <description>2,5mg of felodipin once daily. Duration: 28+-4 days.</description>
    <arm_group_label>felodipin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of hypertension, untreated or currently treated with a maximum of
             one blood pressure (BP) lowering agent

        Exclusion Criteria:

          -  systolic blood pressure &gt;170 mmHg and/or diastolic blood pressure of &gt;105 mmHg

          -  second- or third-degree atrioventricular block

          -  current use of opiates or other intoxicants

          -  neurological disorders (such as Parkinson's disease, multiple sclerosis or peripheral
             neuropathy)

          -  need of treatment with TENS, regardless the reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Silverdal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Geriatrics and Emergency Medicine, Sahlgrenska University Hospital/Östra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Manhem, ass.prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Medicine, Department of Emergency and Cardiovascular Medicine, Sahlgrenska University Hospital/Sahlgrenska</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clas Mannheimer, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Multidisciplinary Pain Center, Sahlgrenska University Hospital/Östra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georgios Mourtzinis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Sahlgrenska University Hospital/Mölndal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabet Stener-Victorin, ass.prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Neuroscience and Physiology, Department of Physiology, University of Gothenburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Geriatrics and Emergency Medicine, Sahlgrenska University Hospital/Östra</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jonas Silverdal MD</name_title>
    <organization>Sahlgrenska University Hospital</organization>
  </responsible_party>
  <keyword>randomized</keyword>
  <keyword>cross-over</keyword>
  <keyword>transcutaneous electrical nerve stimulation</keyword>
  <keyword>felodipin</keyword>
  <keyword>hypertension</keyword>
  <keyword>blood pressure</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

